GSK shares rally as profits dip
Shares in GlaxoSmithKline (GSK) have rallied on the New York Stock Exchange this afternoon (February 6th), after the company announced that its profits have slipped.
The drug giant's pre-tax profits were £7.64 billion for the year to December 31st 2012, which is a four per cent decline on the previous year.
Turnover declined by one per cent to £26.4 billion, as a result of "weaker than expected" sales in Europe, where demand was down by seven per cent.
In the US, sales were down to £8.4 billion – a fall of four per cent – and in Japan, GSK sales slumped by five per cent to £2.2 billion.
Chief executive Sir Andrew Witty said the present operating environment is "challenging", but looking forward to 2013, the company expects to reach earnings per share growth of three or four per cent and sales growth of one per cent.
At 16:40 GMT today, shares in GSK advanced by 0.8 per cent to $45.47 per unit.
Learn about the US markets and CFD trading at City Index.
Comments are closed.
‹ Back to Previous Page
From time to time, City Index Limited’s (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.
As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.